checkAd

     152  0 Kommentare NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology - Seite 4

    Investor Contact:
    Alex Schwartz
    ir@ngmbio.com     		           Media Contact:
    Liz Melone
    media@ngmbio.com
         

    Aktuelle Themen


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology - Seite 4 NGM advances its vision to build the next iconic biologics company, fueled by its in-house discovery engineSignificant progress made across all three therapeutic area portfolios in 2020Phase 2b or Phase 3-enabling studies currently underway for …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer